UTILISATION PHARMACEUTIQUE D'UNE COMPOSITION A BASE DE PIRFENIDONE A LIBERATION PROLONGEE (PFD-LP) POUR LA REVERSION DE LA STEATOSE HEPATIQUE HUMAINE (NAFLD/NASH)
ARMENDARIZ BORUNDA, JUAN SOCORRO,MAGANA CASTRO, JOSE AGUSTIN ROGELIO,HERNANDEZ ALDANA, NADIEL
申请号：
CA3043300
公开号：
CA3043300A1
申请日:
2017.11.09
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
The present invention relates to the use of a pharmaceutical composition in the form of extended-release tablets containing pirfenidone for the treatment of NAFLD / NASH and advanced liver fibrosis, by reducing serum cholesterol and triglycerides, as well as reducing the content of hepatic fat accumulation, both in the form of macrosteatosis and microsteatosis. The invention also relates to the use of the composition as an agonist for PPARgamma (peroxisome proliferation receptor activated gamma), PPARalpha (peroxisome proliferation receptor activated alpha), LXR and CPT1, key molecules in the metabolism of fatty degradation and inflammation of the liver. In addition, another use is the induction of decreased expression of the NFkB master gene, transcriptional inducer of hepatic inflammatory process factor. All of these events result in the reversal of NAFLD / NASH and advanced liver fibrosis.
